DAV Partners with Americans for Ibogaine to Push Psychedelic Research for Veterans

Event summary

  • DAV and Americans for Ibogaine announced a partnership on May 11, 2026 to advance psychedelic therapy research for veterans.
  • The collaboration focuses on ibogaine, a psychoactive compound with potential for treating PTSD, brain injuries, and substance use disorder.
  • DAV will mobilize its nearly 1 million members to advocate for evidence-based ibogaine research in state legislatures.
  • Ibogaine is not federally approved but has seen progress in state-level research and policy discussions.

The big picture

This partnership aligns with the growing interest in psychedelic-assisted therapies for mental health, particularly among veteran populations. DAV's advocacy history and Americans for Ibogaine's policy expertise create a formidable coalition to push for evidence-based treatment options. The collaboration could set a precedent for how nonprofits and advocacy groups engage with emerging therapeutic research.

What we're watching

Regulatory Progress
The pace at which state-level policy developments could accelerate federal approval for ibogaine research.
Advocacy Impact
Whether DAV's mobilization of members can influence state legislatures to prioritize ibogaine research funding.
Research Breakthroughs
How emerging clinical trials may validate ibogaine's efficacy for treating veteran-specific conditions like PTSD.

Related topics

Partnership